Cell-based aptamer
selection (Cell-SELEX) against predefined protein
targets that benefits using the native form of the targets is the
most promising approach to achieve aptamer probes capable of recognizing
targets under both in vitro and in vivo conditions. The major disadvantages
in Cell-SELEX are the imperfectness of the negative selection step
and the lengthy procedure of selection. Here, we introduced the Counter-SELEX
as part of our modified Cell-SELEX and implemented deep sequencing
to overcome these shortcomings in developing aptamers against aspartate
β-hydroxylase (ASPH) as a known tumor marker. In parallel with
the conventional Cell-SELEX, five consecutive cycles of counter selection
were accomplished using sequences bound to negative cells (the Counter-SELEX)
to detect oligos that are not specific for ASPH. After high-throughput
sequencing, the representative of each promising achieved family was
subjected to further confirmatory analysis via flow cytometry, followed
by the fluorescence immunostaining of histopathological sections.
Implementing our innovative complementary method, annoying mis-selected
sequences in Cell-SELEX enriched pools were effectively identified
and removed. According to the affinity assay on the cells displaying
ASPH, three aptamers, AP-Cell 1, AP-Cell 2, and AP-Cell 3, with
K
d
values of 47.51, 39.38, and 65.23 nM, respectively,
were obtained, while AP-Cell 1 and 3 could then successfully spot
ASPH displayed on the tissues. Our study showed that the Counter-SELEX
could be considered as a complementary method for Cell-SELEX to overcome
the imperfectness of the negative selection step. Moreover, high-throughput
nucleotide sequencing could help to shorten the overall process.